Profil
Chulho Park is the founder of Oncotelic, Inc. (founded in 2015) where he holds the title of Chief Technology Officer.
He was also the founder of Mabprex, Inc. (founded in 2010) where he held the title of Chief Executive Officer until 2018.
Dr. Park's former jobs include being the Chief Technology Officer at Oncotelic Therapeutics, Inc. from 2019 to 2021 and being the President-Pharmaceutical Development at IgDraSol, Inc. in 2013.
Aktive Positionen von Chulho Park
| Unternehmen | Position | Beginn |
|---|---|---|
Oncotelic, Inc.
 Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Gründer | 01.01.2015 |
Ehemalige bekannte Positionen von Chulho Park
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2021 |
| Mabprex, Inc. | Vorstandsvorsitzender | 01.01.2018 |
IgDraSol, Inc.
 IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Corporate Officer/Principal | 01.09.2013 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
IgDraSol, Inc.
IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Health Technology |
Oncotelic, Inc.
Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Health Technology |
| Mabprex, Inc. |
